Reported Earnings • May 29
First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.002 loss in 1Q 2025) First quarter 2026 results: EPS: CA$0 (improved from CA$0.002 loss in 1Q 2025). Revenue: CA$42.7k (down 23% from 1Q 2025). Net loss: CA$168.5k (loss narrowed 78% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • May 01
Full year 2025 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in FY 2024) Full year 2025 results: CA$0.004 loss per share (further deteriorated from CA$0.003 loss in FY 2024). Revenue: CA$312.3k (down 34% from FY 2024). Net loss: CA$1.67m (loss widened 45% from FY 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Board Change • Dec 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Joaquin Barbera was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Dec 03
Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0 in 3Q 2024) Third quarter 2025 results: EPS: CA$0 (in line with 3Q 2024). Revenue: CA$35.6k (down 42% from 3Q 2024). Net loss: CA$189.1k (loss widened 7.4% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Board Change • Dec 03
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Joaquin Barbera was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Oct 26
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Joaquin Barbera was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Aug 31
Second quarter 2025 earnings released: EPS: CA$0 (vs CA$0.001 loss in 2Q 2024) Second quarter 2025 results: EPS: CA$0 (improved from CA$0.001 loss in 2Q 2024). Revenue: CA$57.9k (up 2.8% from 2Q 2024). Net loss: CA$202.1k (loss narrowed 39% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Announcement • Aug 26
Blueberries Medical Corp., Annual General Meeting, Oct 22, 2025 Blueberries Medical Corp., Annual General Meeting, Oct 22, 2025. New Risk • May 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.4m free cash flow). Share price has been highly volatile over the past 3 months (55% average daily change). Revenue is less than US$1m (CA$438k revenue, or US$317k). Market cap is less than US$10m (CA$4.95m market cap, or US$3.59m). Minor Risk Shareholders have been diluted in the past year (24% increase in shares outstanding). Reported Earnings • May 30
First quarter 2025 earnings released: CA$0.002 loss per share (vs CA$0.001 loss in 1Q 2024) First quarter 2025 results: CA$0.002 loss per share (further deteriorated from CA$0.001 loss in 1Q 2024). Revenue: CA$55.2k (down 38% from 1Q 2024). Net loss: CA$776.5k (loss widened 201% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 26
Full year 2024 earnings released: CA$0.003 loss per share (vs CA$0.007 loss in FY 2023) Full year 2024 results: CA$0.003 loss per share (improved from CA$0.007 loss in FY 2023). Revenue: CA$471.4k (up 64% from FY 2023). Net loss: CA$1.15m (loss narrowed 30% from FY 2023). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. New Risk • Mar 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (77% average weekly change). Revenue is less than US$1m (CA$266k revenue, or US$186k). Market cap is less than US$10m (CA$4.95m market cap, or US$3.47m). Minor Risk Shareholders have been diluted in the past year (24% increase in shares outstanding). Announcement • Mar 26
Blueberries Medical Corp. announced that it has received CAD 0.726714 million in funding On March 25, 2025, Blueberries Medical Corp. closed the transaction. The company has issued 66,064,935 common shares at a issue price of CAD0.011 per common share for gross proceeds of CAD726,714. The transaction includes investor participation of Facundo Garreton for 66,064,935 shares. Announcement • Mar 08
Blueberries Medical Corp. announced that it expects to receive CAD 1.056714 million in funding Blueberries Medical Corp. announced a non-brokered private placement that it will issue up to 96,064,935 common shares at a price of CAD 0.011 per share for the gross proceeds of up to CAD 1,056,714.285 on March 7, 2025. The Offering is expected to close on or about March 25, 2024. It is expected that the Offering will be led by Terraflos Inc., Guillermo Rodriguez is also expected to participate in the Offering. Reported Earnings • Nov 26
Third quarter 2024 earnings released: EPS: CA$0 (vs CA$0.001 loss in 3Q 2023) Third quarter 2024 results: EPS: CA$0 (improved from CA$0.001 loss in 3Q 2023). Revenue: CA$61.0k (down 27% from 3Q 2023). Net loss: CA$176.0k (loss narrowed 46% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 29
Second quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2023) Second quarter 2024 results: CA$0.001 loss per share (improved from CA$0.002 loss in 2Q 2023). Revenue: CA$56.3k (down 16% from 2Q 2023). Net loss: CA$328.4k (loss narrowed 33% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Announcement • Aug 13
Blueberries Medical Corp., Annual General Meeting, Oct 18, 2024 Blueberries Medical Corp., Annual General Meeting, Oct 18, 2024. Reported Earnings • Jun 04
First quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 1Q 2023) First quarter 2024 results: CA$0.001 loss per share (improved from CA$0.002 loss in 1Q 2023). Revenue: CA$88.9k (up 14% from 1Q 2023). Net loss: CA$258.0k (loss narrowed 41% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. New Risk • Apr 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.4m free cash flow). Shareholders have been substantially diluted in the past year (83% increase in shares outstanding). Revenue is less than US$1m (CA$288k revenue, or US$211k). Market cap is less than US$10m (CA$5.99m market cap, or US$4.38m). Reported Earnings • Nov 25
Third quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 3Q 2022) Third quarter 2023 results: CA$0.001 loss per share (improved from CA$0.002 loss in 3Q 2022). Revenue: CA$83.4k (down 20% from 3Q 2022). Net loss: CA$323.4k (loss narrowed 9.7% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 18
Second quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.003 loss in 2Q 2022) Second quarter 2023 results: CA$0.002 loss per share (improved from CA$0.003 loss in 2Q 2022). Revenue: CA$67.3k (up 69% from 2Q 2022). Net loss: CA$493.3k (loss narrowed 3.6% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Announcement • Aug 18
Blueberries Medical Corp., Annual General Meeting, Oct 06, 2023 Blueberries Medical Corp., Annual General Meeting, Oct 06, 2023. Reported Earnings • Jun 02
First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 1Q 2022) First quarter 2023 results: CA$0.002 loss per share (improved from CA$0.004 loss in 1Q 2022). Revenue: CA$77.9k (up 131% from 1Q 2022). Net loss: CA$440.5k (loss narrowed 33% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 25
Full year 2022 earnings released: CA$0.009 loss per share (vs CA$0.035 loss in FY 2021) Full year 2022 results: CA$0.009 loss per share (improved from CA$0.035 loss in FY 2021). Net loss: CA$1.47m (loss narrowed 72% from FY 2021). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 01
Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.003 loss in 3Q 2021) Third quarter 2022 results: CA$0.002 loss per share (improved from CA$0.003 loss in 3Q 2021). Net loss: CA$358.2k (loss narrowed 16% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Announcement • Nov 29
Blueberries Medical Corp. announced that it has received CAD 1.47147 million in funding from Terraflos Inc. Blueberries Medical Corp. announced a non-brokered private placement of 54,498,889 common shares at a price of CAD 0.027 per common share for aggregate gross proceeds of CAD 1,471,470 led by returning investor Terraflos Inc. on November 28, 2022. Reported Earnings • Aug 26
Second quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 2Q 2021) Second quarter 2022 results: CA$0.003 loss per share (down from CA$0.002 loss in 2Q 2021). Net loss: CA$511.7k (loss widened 90% from 2Q 2021). Announcement • Aug 18
Blueberries Medical Corp., Annual General Meeting, Oct 07, 2022 Blueberries Medical Corp., Annual General Meeting, Oct 07, 2022. Board Change • Mar 29
High number of new directors Independent Director Joaquin Barbera was the last director to join the board, commencing their role in 2021. Reported Earnings • Dec 01
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Third quarter 2021 results: CA$0.003 loss per share (up from CA$0.008 loss in 3Q 2020). Net loss: CA$428.6k (loss narrowed 59% from 3Q 2020). Revenue was in line with analyst estimates. Board Change • Nov 02
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Patricio Villalba is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 02
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Patricio Villalba is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 14
Less than half of directors are independent There are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Patricio Villalba is the most experienced director on the board, commencing their role in 2019. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Announcement • Sep 10
Blueberries Medical Corp. announced that it has received CAD 1.901382 million in funding from Terraflos Inc. Blueberries Medical Corp. announced a private placement of 19,013,817 common shares at a price of CAD 0.10 per share for gross proceeds of CAD 1,901,382 on September 9, 2021. The transaction was led by Terraflos Inc.. Executive Departure • Jun 08
Chief Financial Officer Ian Atacan has left the company During their tenure, earnings grew by 48% annually compared to the industry average of 12%. On the 1st of June, Ian Atacan left the company after 1.9 in the role. As of March 2021, Ian still personally held 965.00k shares (CA$174k worth at the time). Ian is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Announcement • Feb 11
Blueberries Medical Corp. Appoints José María Forero as President of Latin American Operations, Effective February 16, 2021 Blueberries Medical Corp. announced the appointment of José María Forero, the former Global Head of B2B of Clever Leaves Holdings Inc. as President of Latin American Operations, effective February 16, 2021. Mr. Forero is a C-level executive with 17+ years of regional and global experience in sales having led successful development of commercial departments within numerous companies, including most recently Clever Leaves, the medical cannabis licensed producer in Colombia. Mr. Forero is an Industrial Engineer and has an Executive MBA degree from INALDE Busines School. Is New 90 Day High Low • Feb 11
New 90-day high: CA$0.23 The company is up 411% from its price of CA$0.045 on 12 November 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 109% over the same period. Announcement • Jul 18
Blueberries Medical Corp. announced that it has received CAD 1 million in funding Blueberries Medical Corp. (CNSX:BBM) announced a non-brokered private placement of unsecured convertible debentures on July 16, 2020. The transaction will include participation from Glassford S.A. represented by Facundo Garreton. The debentures will be issued at par. The debentures are unsecured and are convertible at a fixed conversion price of CAD 0.065 per share into 12,533,030 common shares. 